<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.3.433">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">

<meta name="author" content="Kaspar Rufibach (input and review of Roche colleagues, especially Marcel Wolbers, gratefully acknowledged)">

<title>Oncology Estimand WG - New-anti lymphoma treatment (NALT) as intercurrent event for PFS in lymphoma</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
  vertical-align: middle;
}
/* CSS for citations */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging-indent div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}</style>


<script src="site_libs/quarto-nav/quarto-nav.js"></script>
<script src="site_libs/quarto-nav/headroom.min.js"></script>
<script src="site_libs/clipboard/clipboard.min.js"></script>
<script src="site_libs/quarto-search/autocomplete.umd.js"></script>
<script src="site_libs/quarto-search/fuse.min.js"></script>
<script src="site_libs/quarto-search/quarto-search.js"></script>
<meta name="quarto:offset" content="./">
<script src="site_libs/quarto-html/quarto.js"></script>
<script src="site_libs/quarto-html/popper.min.js"></script>
<script src="site_libs/quarto-html/tippy.umd.min.js"></script>
<script src="site_libs/quarto-html/anchor.min.js"></script>
<link href="site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="site_libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="site_libs/bootstrap/bootstrap.min.js"></script>
<link href="site_libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="site_libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">
<script id="quarto-search-options" type="application/json">{
  "location": "navbar",
  "copy-button": false,
  "collapse-after": 3,
  "panel-placement": "end",
  "type": "overlay",
  "limit": 20,
  "language": {
    "search-no-results-text": "No results",
    "search-matching-documents-text": "matching documents",
    "search-copy-link-title": "Copy link to search",
    "search-hide-matches-text": "Hide additional matches",
    "search-more-match-text": "more match in this document",
    "search-more-matches-text": "more matches in this document",
    "search-clear-button-title": "Clear",
    "search-detached-cancel-button-title": "Cancel",
    "search-submit-button-title": "Submit",
    "search-label": "Search"
  }
}</script>

  <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
  <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml-full.js" type="text/javascript"></script>

<link rel="stylesheet" href="styles.css">
</head>

<body class="nav-fixed">

<div id="quarto-search-results"></div>
  <header id="quarto-header" class="headroom fixed-top">
    <nav class="navbar navbar-expand-lg navbar-dark ">
      <div class="navbar-container container-fluid">
      <div class="navbar-brand-container">
    <a class="navbar-brand" href="./index.html">
    <span class="navbar-title">Oncology Estimand WG</span>
    </a>
  </div>
            <div id="quarto-search" class="" title="Search"></div>
          <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarCollapse" aria-controls="navbarCollapse" aria-expanded="false" aria-label="Toggle navigation" onclick="if (window.quartoToggleHeadroom) { window.quartoToggleHeadroom(); }">
  <span class="navbar-toggler-icon"></span>
</button>
          <div class="collapse navbar-collapse" id="navbarCollapse">
            <ul class="navbar-nav navbar-nav-scroll me-auto">
  <li class="nav-item dropdown ">
    <a class="nav-link dropdown-toggle" href="#" id="nav-menu-about" role="button" data-bs-toggle="dropdown" aria-expanded="false" rel="" target="">
 <span class="menu-text">About</span>
    </a>
    <ul class="dropdown-menu" aria-labelledby="nav-menu-about">    
        <li>
    <a class="dropdown-item" href="./index.html" rel="" target="">
 <span class="dropdown-text">About</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./updates.html" rel="" target="">
 <span class="dropdown-text">Updates of this page</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./history.html" rel="" target="">
 <span class="dropdown-text">History</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./scope.html" rel="" target="">
 <span class="dropdown-text">Scope</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./status.html" rel="" target="">
 <span class="dropdown-text">Status</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./organization.html" rel="" target="">
 <span class="dropdown-text">Organization</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./collaborations.html" rel="" target="">
 <span class="dropdown-text">Collaborations</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./achievements.html" rel="" target="">
 <span class="dropdown-text">Achievements per year</span></a>
  </li>  
    </ul>
  </li>
  <li class="nav-item">
    <a class="nav-link" href="./taskforces.html" rel="" target="">
 <span class="menu-text">Task forces</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="./ha.html" rel="" target="">
 <span class="menu-text">Health authority interactions</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="./publications.html" rel="" target="">
 <span class="menu-text">Publications</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="./code.html" rel="" target="">
 <span class="menu-text">Code</span></a>
  </li>  
  <li class="nav-item dropdown ">
    <a class="nav-link dropdown-toggle" href="#" id="nav-menu-events" role="button" data-bs-toggle="dropdown" aria-expanded="false" rel="" target="">
 <span class="menu-text">Events</span>
    </a>
    <ul class="dropdown-menu" aria-labelledby="nav-menu-events">    
        <li>
    <a class="dropdown-item" href="./events_upcoming.html" rel="" target="">
 <span class="dropdown-text">Upcoming events</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./events_past.html" rel="" target="">
 <span class="dropdown-text">Past events</span></a>
  </li>  
    </ul>
  </li>
  <li class="nav-item dropdown ">
    <a class="nav-link dropdown-toggle" href="#" id="nav-menu-communication" role="button" data-bs-toggle="dropdown" aria-expanded="false" rel="" target="">
 <span class="menu-text">Communication</span>
    </a>
    <ul class="dropdown-menu" aria-labelledby="nav-menu-communication">    
        <li>
    <a class="dropdown-item" href="./news.html" rel="" target="">
 <span class="dropdown-text">Newsletters</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="./videos.html" rel="" target="">
 <span class="dropdown-text">Linkedin videos</span></a>
  </li>  
    </ul>
  </li>
  <li class="nav-item">
    <a class="nav-link" href="./resources.html" rel="" target="">
 <span class="menu-text">Further resources</span></a>
  </li>  
</ul>
            <div class="quarto-navbar-tools ms-auto">
</div>
          </div> <!-- /navcollapse -->
      </div> <!-- /container-fluid -->
    </nav>
</header>
<!-- content -->
<div id="quarto-content" class="quarto-container page-columns page-rows-contents page-layout-article page-navbar">
<!-- sidebar -->
<!-- margin-sidebar -->
    <div id="quarto-margin-sidebar" class="sidebar margin-sidebar">
        <nav id="TOC" role="doc-toc" class="toc-active">
    <h2 id="toc-title">On this page</h2>
   
  <ul>
  <li><a href="#context" id="toc-context" class="nav-link active" data-scroll-target="#context">Context</a></li>
  <li><a href="#estimand" id="toc-estimand" class="nav-link" data-scroll-target="#estimand">Estimand</a>
  <ul class="collapse">
  <li><a href="#implicit-hypothetical-strategy-for-the-ice-of-nalt" id="toc-implicit-hypothetical-strategy-for-the-ice-of-nalt" class="nav-link" data-scroll-target="#implicit-hypothetical-strategy-for-the-ice-of-nalt">(implicit) Hypothetical strategy for the ICE of NALT</a></li>
  <li><a href="#implicit-treatment-policy-strategy-for-the-ice-of-nalt" id="toc-implicit-treatment-policy-strategy-for-the-ice-of-nalt" class="nav-link" data-scroll-target="#implicit-treatment-policy-strategy-for-the-ice-of-nalt">(implicit) Treatment policy strategy for the ICE of NALT</a></li>
  </ul></li>
  <li><a href="#fda-view-on-hypothetical-strategy-in-general" id="toc-fda-view-on-hypothetical-strategy-in-general" class="nav-link" data-scroll-target="#fda-view-on-hypothetical-strategy-in-general">FDA view on hypothetical strategy in general</a></li>
  <li><a href="#estimation-methods" id="toc-estimation-methods" class="nav-link" data-scroll-target="#estimation-methods">Estimation methods</a>
  <ul class="collapse">
  <li><a href="#censoring" id="toc-censoring" class="nav-link" data-scroll-target="#censoring">Censoring</a></li>
  <li><a href="#other-estimators-of-an-estimand-with-a-hypothetical-strategy-for-an-ice" id="toc-other-estimators-of-an-estimand-with-a-hypothetical-strategy-for-an-ice" class="nav-link" data-scroll-target="#other-estimators-of-an-estimand-with-a-hypothetical-strategy-for-an-ice">Other estimators of an estimand with a hypothetical strategy for an ICE</a></li>
  <li><a href="#if-you-censor-treatment-switches-are-you-somehow-inducing-non-random-non-independent-censoring-especially-in-the-context-of-external-controls-where-cross-over-is-more-limited-in-trials-and-switches-are-more-common-in-rwd" id="toc-if-you-censor-treatment-switches-are-you-somehow-inducing-non-random-non-independent-censoring-especially-in-the-context-of-external-controls-where-cross-over-is-more-limited-in-trials-and-switches-are-more-common-in-rwd" class="nav-link" data-scroll-target="#if-you-censor-treatment-switches-are-you-somehow-inducing-non-random-non-independent-censoring-especially-in-the-context-of-external-controls-where-cross-over-is-more-limited-in-trials-and-switches-are-more-common-in-rwd">If you censor treatment switches, are you somehow inducing non-random / non-independent censoring, especially in the context of external controls where cross-over is more limited in trials and switches are more common in RWD?</a></li>
  </ul></li>
  <li><a href="#publicly-available-comments-on-molecules" id="toc-publicly-available-comments-on-molecules" class="nav-link" data-scroll-target="#publicly-available-comments-on-molecules">Publicly available comments on molecules</a>
  <ul class="collapse">
  <li><a href="#polarix-odac" id="toc-polarix-odac" class="nav-link" data-scroll-target="#polarix-odac">Polarix ODAC</a>
  <ul class="collapse">
  <li><a href="#what-is-the-primary-question-of-interest" id="toc-what-is-the-primary-question-of-interest" class="nav-link" data-scroll-target="#what-is-the-primary-question-of-interest">What is the primary question of interest?</a></li>
  <li><a href="#relation-between-treatment-policy-and-hypothetical-strategy-for-an-ice-of-nalt" id="toc-relation-between-treatment-policy-and-hypothetical-strategy-for-an-ice-of-nalt" class="nav-link" data-scroll-target="#relation-between-treatment-policy-and-hypothetical-strategy-for-an-ice-of-nalt">Relation between treatment policy and hypothetical strategy for an ICE of NALT</a></li>
  <li><a href="#consistency-between-estimates-for-two-different-estimands" id="toc-consistency-between-estimates-for-two-different-estimands" class="nav-link" data-scroll-target="#consistency-between-estimates-for-two-different-estimands">Consistency between estimates for two different estimands</a></li>
  <li><a href="#further-trials-where-roche-received-similar-feedback" id="toc-further-trials-where-roche-received-similar-feedback" class="nav-link" data-scroll-target="#further-trials-where-roche-received-similar-feedback">Further trials where Roche received similar feedback</a></li>
  </ul></li>
  <li><a href="#sotorasib-odac" id="toc-sotorasib-odac" class="nav-link" data-scroll-target="#sotorasib-odac">Sotorasib ODAC</a></li>
  <li><a href="#qing-xus-presentation-at-asa-biopharmaceutical-section-regulatory-industry-statistics-workshop" id="toc-qing-xus-presentation-at-asa-biopharmaceutical-section-regulatory-industry-statistics-workshop" class="nav-link" data-scroll-target="#qing-xus-presentation-at-asa-biopharmaceutical-section-regulatory-industry-statistics-workshop">Qing Xu’s presentation at ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop</a>
  <ul class="collapse">
  <li><a href="#non-random-censoring" id="toc-non-random-censoring" class="nav-link" data-scroll-target="#non-random-censoring">Non-random censoring</a></li>
  <li><a href="#different-estimands-to-quantify-the-effect" id="toc-different-estimands-to-quantify-the-effect" class="nav-link" data-scroll-target="#different-estimands-to-quantify-the-effect">Different estimands to quantify the effect:</a></li>
  </ul></li>
  </ul></li>
  <li><a href="#fda-lungevity-statistical-forum-12th-october-impact-of-cross-over-in-the-evaluation-of-overall-survival-in-randomized-cancer-clinical-trials" id="toc-fda-lungevity-statistical-forum-12th-october-impact-of-cross-over-in-the-evaluation-of-overall-survival-in-randomized-cancer-clinical-trials" class="nav-link" data-scroll-target="#fda-lungevity-statistical-forum-12th-october-impact-of-cross-over-in-the-evaluation-of-overall-survival-in-randomized-cancer-clinical-trials">FDA / Lungevity statistical forum 12th October: Impact of Cross-over in the Evaluation of Overall Survival in Randomized Cancer Clinical Trials</a></li>
  <li><a href="#patient-participation" id="toc-patient-participation" class="nav-link" data-scroll-target="#patient-participation">Patient participation</a></li>
  <li><a href="#appendix" id="toc-appendix" class="nav-link" data-scroll-target="#appendix">Appendix</a></li>
  <li><a href="#why-is-censoring-of-subjects-in-the-estimator-for-a-time-to-event-endpoint-implementing-a-hypothetical-strategy" id="toc-why-is-censoring-of-subjects-in-the-estimator-for-a-time-to-event-endpoint-implementing-a-hypothetical-strategy" class="nav-link" data-scroll-target="#why-is-censoring-of-subjects-in-the-estimator-for-a-time-to-event-endpoint-implementing-a-hypothetical-strategy">Why is censoring of subjects in the estimator for a time-to-event endpoint implementing a hypothetical strategy?</a></li>
  <li><a href="#references" id="toc-references" class="nav-link" data-scroll-target="#references">References</a></li>
  </ul>
</nav>
    </div>
<!-- main -->
<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title">New-anti lymphoma treatment (NALT) as intercurrent event for PFS in lymphoma</h1>
</div>


<div class="quarto-title-meta-author">
  <div class="quarto-title-meta-heading">Author</div>
  <div class="quarto-title-meta-heading">Affiliation</div>
  
    <div class="quarto-title-meta-contents">
    <p class="author">Kaspar Rufibach (input and review of Roche colleagues, especially Marcel Wolbers, gratefully acknowledged) </p>
  </div>
    <div class="quarto-title-meta-contents">
        <p class="affiliation">
            Methods, Collaboration, and Outreach (MCO) Group, Roche
          </p>
      </div>
    </div>

<div class="quarto-title-meta">

      
  
    
  </div>
  

</header>

<section id="context" class="level1">
<h1>Context</h1>
<p>New anti-lymphoma (NALT) therapy before progression (PD) for progression-free survival (PFS) in lymphoma trials can be considered an intercurrent event (ICE) in the framework of the <a href="https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf">ICH E9 addendum</a> addendum. This raises the following questions:</p>
<ul>
<li>What clinical question are we interested in?</li>
<li>Which of the five estimand strategies in the <a href="https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf">ICH E9 addendum</a> help answering the clinical question of interest?</li>
<li>How should we estimate the chosen estimand?</li>
</ul>
</section>
<section id="estimand" class="level1">
<h1>Estimand</h1>
<section id="implicit-hypothetical-strategy-for-the-ice-of-nalt" class="level2">
<h2 class="anchored" data-anchor-id="implicit-hypothetical-strategy-for-the-ice-of-nalt">(implicit) Hypothetical strategy for the ICE of NALT</h2>
<p>In the 00’s, i.e.&nbsp;in the pre-estimand addendum era, there already was a debate whether one should censor at start of NALT in lymphoma indications, and this debates appears to go on until today. The FDA guidance <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics"><em>Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics</em></a> <span class="citation" data-cites="fda_endpoints">U.S. Food and Drug Administration (<a href="#ref-fda_endpoints" role="doc-biblioref">2007</a>)</span> recommends to censor at date of “new anticancer treatment”. This is in line with <a href="papers/Cheson et al (2007) Revised response criteria for malignant lymphoma.pdf">Cheson et al. <span class="citation" data-cites="cheson_07">(<span>2007</span>)</span></a> who writes</p>
<blockquote class="blockquote">
<p>…in studies in which failure to respond without progression is considered an indication for another therapy, such patients should be censored at that point for the progression analysis.</p>
</blockquote>
<p>This estimator, i.e.&nbsp;censoring at start of NALT, (implicitly) corresponds to applying a <strong>hypothetical</strong> strategy for the ICE of NALT. <strong>This means it specifies interest in a treatment effect in a world where NALT would not exist.</strong></p>
</section>
<section id="implicit-treatment-policy-strategy-for-the-ice-of-nalt" class="level2">
<h2 class="anchored" data-anchor-id="implicit-treatment-policy-strategy-for-the-ice-of-nalt">(implicit) Treatment policy strategy for the ICE of NALT</h2>
<p>Interestingly, in another highly cited paper by <a href="papers/Fleming et al (2009) Issues in Using PFS When Evaluating Oncology Products.pdf">Fleming et al. <span class="citation" data-cites="fleming_09">(<span>2009</span>)</span></a>, it is recommended that</p>
<blockquote class="blockquote">
<p>…patients should not be censored at the time other treatments are initiated when analyzing the PFS end point…</p>
</blockquote>
<p>This corresponds to a <strong>treatment policy</strong> estimand. This is also implicitly the recommendation in the EMA guidance <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/appendix-1-guideline-evaluation-anticancer-medicinal-products-man-methodological-consideration-using_en.pdf">Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man</a>:</p>
<blockquote class="blockquote">
<p>The time of the progression or recurrence event is determined using the first date when there is documented evidence that the criteria have been met, even in situations where progression is observed after one or more missed visits, treatment discontinuation, or <strong>new anti-cancer treatment</strong>.</p>
</blockquote>
<p><strong>A treatment policy strategy for the ICE of NALT can be interpreted as treatment effect for the treatment strategy</strong></p>
<p><em>start with therapy at randomization + switch to approved NALT before PD according to investigator’s choice.</em></p>
<p><strong>This appears to come closest to the treatment effect that will be observed in the “real world” once the drug is approved, because approved NALTs will be available.</strong></p>
<p>A treatment policy strategy for start of 2nd line therapy for an endpoint of PFS has, e.g., been implemented in all pivotal Roche Gazyva trials (Gadolin, Gallium, Goya).</p>
</section>
</section>
<section id="fda-view-on-hypothetical-strategy-in-general" class="level1">
<h1>FDA view on hypothetical strategy in general</h1>
<p><a href="papers/Ionan et al (2023), Clinical and Statistical Perspectives on the Estimand Framework Implementation.pdf">Ionan et al <span class="citation" data-cites="ionan_22">(<span>2022</span>)</span></a> comment:</p>
<blockquote class="blockquote">
<p>For example, in the case of a hypothetical strategy, it is necessary to describe precisely the nature of the hypothetical scenario under which estimation of treatment effect is of interest and why the actual scenario in which the intercurrent event occurs is problematic for the interpretation of the treatment effect. It is important to justify the relevance of the corresponding treatment effect to be estimated, and the statistical model that accurately captures the specific chosen hypothetical scenario.</p>
</blockquote>
<p>and</p>
<blockquote class="blockquote">
<p>The clinical and regulatory interest of such hypotheticals is limited and would usually depend on a clear understanding of why and how the intercurrent event, or its consequences, would be expected to be different in clinical practice than in the clinical trial.</p>
</blockquote>
<p>So, using a hypothetical strategy for the ICE of NALT corresponds to interest in a treatment effect in a world where <strong>such NALT would not exist</strong>.</p>
<p>Similarly, FDA colleagues <a href="papers/Mayo and Kim (2023) What can be Achieved with the Estimand Framework.pdf">Mayo and Kim <span class="citation" data-cites="mayo_23">(<span>2023</span>)</span></a> discourage use of hypothetical estimands:</p>
<blockquote class="blockquote">
<p>More precisely defining the clinical question and corresponding estimand has led to some challenges and differences in perspectives. For example, it is uncommon that we have found a hypothetical strategy to be the most relevant one for the primary clinical question used in regulatory decision-making (with exceptions, e.g., a pandemic leading to temporary site closures that are not expected to occur in general clinical practice in the future).</p>
</blockquote>
</section>
<section id="estimation-methods" class="level1">
<h1>Estimation methods</h1>
<section id="censoring" class="level2">
<h2 class="anchored" data-anchor-id="censoring">Censoring</h2>
<p>Some of the estimand aspects have been mingled into the, what we now call “estimand discussion” in the past. Most specifically, the question about “censoring”. Censoring is a statistical technique to estimate an estimand with a hypothetical strategy for an ICE. As such, “censoring” cannot be part of the <em>estimand</em> definition, rather it pertains to the <em>estimation method</em>.</p>
<p>Furthermore, for an estimator based on censoring to give an unbiased estimate of the targeted estimand which uses a hypothetical strategy for the ICE of interest one needs to make quite strong assumptions, either that censoring is <strong>random</strong> or at least <strong>independent</strong>. The latter is a slightly weaker assumption, see <a href="papers/Andersen (2005, encyclopedia) Censored data.pdf">Andersen <span class="citation" data-cites="andersen_05">(<span>2005</span>)</span></a>. Not that <strong>informative censoring</strong> is yet another concept – although often used in pharmaceutical statistician’s discussions (in the sense of “non-informative”) it is actually mathematically not the correct term for what we are talking about here, see <a href="papers/Andersen (2005, encyclopedia) Censored data.pdf">Andersen <span class="citation" data-cites="andersen_05">(<span>2005</span>)</span></a>.</p>
</section>
<section id="other-estimators-of-an-estimand-with-a-hypothetical-strategy-for-an-ice" class="level2">
<h2 class="anchored" data-anchor-id="other-estimators-of-an-estimand-with-a-hypothetical-strategy-for-an-ice">Other estimators of an estimand with a hypothetical strategy for an ICE</h2>
<p>Sometimes it might be plausible that subjects who discontinued treatment early would have done worse than those who did not, <strong>even in a hypothetical world where they had stayed on treatment</strong>. One method for imputing T2E endpoints in this case is the method by Jackson et al. <span class="citation" data-cites="jackson_14">(<a href="#ref-jackson_14" role="doc-biblioref">2014</a>)</span> which is implemented in the <a href="https://cran.r-project.org/package=InformativeCensoring">InformativeCensoring</a> <a href="https://cran.r-project.org">R</a> package. A caveat of this method is that it depends on <span class="math inline">\(\gamma\)</span>, the hypothesized size of the step change in the log hazard at censoring. This makes it not easy to have this approach as a primary analysis, but potentially as sensitivity analysis.</p>
<p>Alternatively, inverse-probability of censoring weights (IPCW) has also been proposed. Here, patients who do not have the intercurrent event serve as proxies for those who do. For estimation we need covariates that make PFS and the intercurrent event conditionally independent. An advantage of IPCW is that you can include updated time-varying covariates in the <em>probability of censoring</em> model, which might make the required assumptions more plausible. One practical issue with the approach are unstable weights. Again, this can most likely be positioned as sensitivity analysis.</p>
</section>
<section id="if-you-censor-treatment-switches-are-you-somehow-inducing-non-random-non-independent-censoring-especially-in-the-context-of-external-controls-where-cross-over-is-more-limited-in-trials-and-switches-are-more-common-in-rwd" class="level2">
<h2 class="anchored" data-anchor-id="if-you-censor-treatment-switches-are-you-somehow-inducing-non-random-non-independent-censoring-especially-in-the-context-of-external-controls-where-cross-over-is-more-limited-in-trials-and-switches-are-more-common-in-rwd">If you censor treatment switches, are you somehow inducing non-random / non-independent censoring, especially in the context of external controls where cross-over is more limited in trials and switches are more common in RWD?</h2>
<p>Yes, generally treatment switches are often informative (which does not mean censoring is informative, see <a href="papers/Andersen (2005, encyclopedia) Censored data.pdf">Andersen <span class="citation" data-cites="andersen_05">(<span>2005</span>)</span></a>) as people are switching because their current treatment is not working. However, you could also imagine some scenarios where the reason for switching may not carry information about a patient, e.g.&nbsp;a region may limit the availability of a certain treatment to a limited number of cycles for cost-effectiveness reasons.</p>
</section>
</section>
<section id="publicly-available-comments-on-molecules" class="level1">
<h1>Publicly available comments on molecules</h1>
<section id="polarix-odac" class="level2">
<h2 class="anchored" data-anchor-id="polarix-odac">Polarix ODAC</h2>
<p>Whether to censor at NALT or not was a question in the <a href="https://www.fda.gov/advisory-committees/advisory-committee-calendar/march-9-2023-meeting-oncologic-drugs-advisory-committee-meeting-announcement-03092023">Polarix ODAC</a>.</p>
<p>FDA’s comments are available in Appendix 2 (p.&nbsp;95ff) of <a href="https://www.fda.gov/media/165961/download">Genentech’s briefing package</a>. Here, we summarize our view on some of FDA’s comments.</p>
<section id="what-is-the-primary-question-of-interest" class="level3">
<h3 class="anchored" data-anchor-id="what-is-the-primary-question-of-interest">What is the primary question of interest?</h3>
<p>FDA’s proposed analysis of censoring at NALT, implying a hypothetical strategy for the ICE of NALT, insinuates interest in a treatment effect in a world where NALT would not exist. However, if Polivy is approved NALT will be available for patients.</p>
</section>
<section id="relation-between-treatment-policy-and-hypothetical-strategy-for-an-ice-of-nalt" class="level3">
<h3 class="anchored" data-anchor-id="relation-between-treatment-policy-and-hypothetical-strategy-for-an-ice-of-nalt">Relation between treatment policy and hypothetical strategy for an ICE of NALT</h3>
<p>FDA comments:</p>
<blockquote class="blockquote">
<p>When comparing the treatment policy approach and the hypothetical approach, there are advantages and caveats to both.</p>
</blockquote>
<p>First and foremost, they answer <strong>different</strong> clinical questions. In our opinion which question is of most interest should guide the discussion.</p>
</section>
<section id="consistency-between-estimates-for-two-different-estimands" class="level3">
<h3 class="anchored" data-anchor-id="consistency-between-estimates-for-two-different-estimands">Consistency between estimates for two different estimands</h3>
<p>FDA commented that</p>
<blockquote class="blockquote">
<p>Therefore, neither approach is perfect and both strategies are important to characterize the effect of treatment. Ideally, they should be consistent and come to the same conclusion to demonstrate a robust PFS benefit.</p>
</blockquote>
<p>Different handling of NALT corresponds to different estimands and we do not see a need that the answer to different scientific questions must necessarily be consistent.</p>
</section>
<section id="further-trials-where-roche-received-similar-feedback" class="level3">
<h3 class="anchored" data-anchor-id="further-trials-where-roche-received-similar-feedback">Further trials where Roche received similar feedback</h3>
<ul>
<li>Polivy: <a href="https://www.clinicaltrials.gov/study/NCT03274492?distance=50&amp;titles=polarix&amp;rank=1">Polarix</a>, <a href="https://www.clinicaltrials.gov/study/NCT04182204?rank=1&amp;limit=10&amp;titles=polargo">Polargo</a>.</li>
<li>Mosunetuzumab: <a href="https://www.clinicaltrials.gov/study/NCT05171647?rank=1&amp;limit=10&amp;titles=Sunmo">Sunmo</a>, <a href="https://www.clinicaltrials.gov/study/NCT04712097?rank=1&amp;limit=10&amp;titles=Celestimo">Celestimo</a>.</li>
<li>Glofitamab: <a href="https://clinicaltrials.gov/study/NCT04408638">Starglo</a>, <a href="https://www.clinicaltrials.gov/study/NCT06047080?titles=NCT06047080&amp;rank=1">Skyglo</a>.</li>
</ul>
</section>
</section>
<section id="sotorasib-odac" class="level2">
<h2 class="anchored" data-anchor-id="sotorasib-odac">Sotorasib ODAC</h2>
<p><a href="https://www.fda.gov/media/172696/download">Briefing document</a>.</p>
</section>
<section id="qing-xus-presentation-at-asa-biopharmaceutical-section-regulatory-industry-statistics-workshop" class="level2">
<h2 class="anchored" data-anchor-id="qing-xus-presentation-at-asa-biopharmaceutical-section-regulatory-industry-statistics-workshop">Qing Xu’s presentation at ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop</h2>
<p><a href="https://oncoestimand.github.io/oncowg_webpage/docs/talks/20230929/1_Xu.pdf">Slidedeck</a>.</p>
<section id="non-random-censoring" class="level3">
<h3 class="anchored" data-anchor-id="non-random-censoring">Non-random censoring</h3>
<p>We would argue that foremost, a discussion of the estimand is needed before discussing estimation methods.</p>
</section>
<section id="different-estimands-to-quantify-the-effect" class="level3">
<h3 class="anchored" data-anchor-id="different-estimands-to-quantify-the-effect">Different estimands to quantify the effect:</h3>
<p>Summary comment:</p>
<blockquote class="blockquote">
<p>Different methods with different Estimand strategies should be conducted to ensure robustness. No single Estimand that fits all needs.</p>
</blockquote>
<p>We agree to the general concept that multiple estimands will help quantify the treatment effect. However, that raises the question about whether and how to pick the primary estimand and how to decide about “success” of the trial.</p>
</section>
</section>
</section>
<section id="fda-lungevity-statistical-forum-12th-october-impact-of-cross-over-in-the-evaluation-of-overall-survival-in-randomized-cancer-clinical-trials" class="level1">
<h1>FDA / Lungevity statistical forum 12th October: Impact of Cross-over in the Evaluation of Overall Survival in Randomized Cancer Clinical Trials</h1>
<p>Speakers:</p>
<ul>
<li>Prof.&nbsp;Nicholas R Latimer, University of Sheffield, UK</li>
<li>Prof.&nbsp;Cheng Zheng, University of Nebraska, US</li>
<li>Dr.&nbsp;Kaspar Rufibach, Roche Pharma, Switzerland</li>
</ul>
<p>Slides of Kaspar Rufibach’s presentation are available <a href="https://numbersman77.github.io/kasparrufibach/files/talks/20231012_Rufibach_Lungevity_crossover.pdf">here</a>.</p>
<p>Many of the above topics were raised in Kaspar’s presentation, sharing Roche’s experience in FDA interactions on Glofitamab. An additional point was that FDA suggested a hypothetical strategy for NALT for PFS, but discouraged a similar hypothetical strategy for crossover for OS.</p>
</section>
<section id="patient-participation" class="level1">
<h1>Patient participation</h1>
<p>We mention here <a href="papers/Rubin et al (2017) Strategies to Maximize Patient Participation in Clinical Trials.pdf">Rubin et al. <span class="citation" data-cites="rubin_17">(<span>2017</span>)</span></a>.</p>
</section>
<section id="appendix" class="level1">
<h1>Appendix</h1>
</section>
<section id="why-is-censoring-of-subjects-in-the-estimator-for-a-time-to-event-endpoint-implementing-a-hypothetical-strategy" class="level1">
<h1>Why is censoring of subjects in the estimator for a time-to-event endpoint implementing a hypothetical strategy?</h1>
<p>Assume you have a trial with 100 patients and primary endpoint PFS. (In a frequentist world) This trial is a sample drawn from a metaphysical population, where the latter is our primary interest and one of the attributes of the estimand defintion. In the population PFS has a true survival function <span class="math inline">\(S\)</span>.</p>
<p>In a first scenario, assume you observe PFS for all the 100 patients. Then, an unbiased estimator <span class="math inline">\(\hat S_1\)</span>, such as e.g.&nbsp;Kaplan-Meier (which in this case is nothing else than 1 - CDF), estimates <span class="math inline">\(S\)</span>.</p>
<p>Now assume a second scenario where 20 patients are <strong>randomly censored</strong> (following the terminology in Unkel et al. <span class="citation" data-cites="unkel_19">(<a href="#ref-unkel_19" role="doc-biblioref">2019</a>)</span>, based on <span class="citation" data-cites="aalen_08">Aalen, Borgan, and Gjessing (<a href="#ref-aalen_08" role="doc-biblioref">2008</a>)</span>). If we now estimate <span class="math inline">\(S\)</span> using an unbiased estimator <span class="math inline">\(\hat S_2\)</span>, e.g.&nbsp;Kaplan-Meier, again then we are “correctly” using the information of the 20 censored patients, i.e.&nbsp;for these 20 patients “…outcome after <span class="math inline">\(x\)</span> number of months is imputed by using the longer term outcomes of other patients in their treatment group who also are free of the outcome at <span class="math inline">\(x\)</span> number of months and remain under follow-up beyond <span class="math inline">\(x\)</span> number of months.” (terminology used in <a href="papers/Fleming et al (2009) Issues in Using PFS When Evaluating Oncology Products.pdf">Fleming et al. <span class="citation" data-cites="fleming_09">(<span>2009</span>)</span></a>). So indeed, the estimand we are targeting (namely the function <span class="math inline">\(S\)</span>) remains the same as in the hypothetical world where censoring would not happen.</p>
<p>It is important to note that censoring alone is only sufficient for implementing a hypothetical strategy if censoring is, e.g., <strong>random</strong> in the sense described in, e.g., Unkel et al. <span class="citation" data-cites="unkel_19">(<a href="#ref-unkel_19" role="doc-biblioref">2019</a>)</span>. This is essentially equivalent to the “missing-at-random” assumption for longitudinal outcomes.</p>
</section>
<section id="references" class="level1">




</section>

<div id="quarto-appendix" class="default"><section class="quarto-appendix-contents" role="doc-bibliography"><h2 class="anchored quarto-appendix-heading">References</h2><div id="refs" class="references csl-bib-body hanging-indent" role="list">
<div id="ref-aalen_08" class="csl-entry" role="listitem">
Aalen, Odd, Ørnulf Borgan, and Haakon Gjessing. 2008. <em>Sur.vival and Event History Analysis: A Process Point of View</em>. Springer Science &amp; Business Media.
</div>
<div id="ref-andersen_05" class="csl-entry" role="listitem">
Andersen, Per Kragh. 2005. <span>“Censored Data.”</span> In <em>Encyclopedia of Biostatistics</em>. John Wiley &amp; Sons, Ltd. <a href="https://doi.org/10.1002/0470011815.b2a11008">https://doi.org/10.1002/0470011815.b2a11008</a>.
</div>
<div id="ref-cheson_07" class="csl-entry" role="listitem">
Cheson, B. D., B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, et al. 2007. <span>“<span class="nocase"><span>R</span>evised response criteria for malignant lymphoma</span>.”</span> <em>J. Clin. Oncol.</em> 25 (5): 579–86.
</div>
<div id="ref-fleming_09" class="csl-entry" role="listitem">
Fleming, T. R., M. D. Rothmann, and H. L. Lu. 2009. <span>“<span class="nocase"><span>I</span>ssues in using progression-free survival when evaluating oncology products</span>.”</span> <em>J. Clin. Oncol.</em> 27 (17): 2874–80.
</div>
<div id="ref-ionan_22" class="csl-entry" role="listitem">
Ionan, Alexei C., Miya Paterniti, Devan V. Mehrotra, John Scott, Bohdana Ratitch, Sylva Collins, Shanti Gomatam, Lei Nie, Kaspar Rufibach, and Frank Bretz. 2022. <span>“Clinical and Statistical Perspectives on the ICH E9(R1) Estimand Framework Implementation.”</span> <em>Statistics in Biopharmaceutical Research</em> 0 (ja): 1–12. <a href="https://doi.org/10.1080/19466315.2022.2081601">https://doi.org/10.1080/19466315.2022.2081601</a>.
</div>
<div id="ref-jackson_14" class="csl-entry" role="listitem">
Jackson, Dan, Ian R. White, Shaun Seaman, Hannah Evans, Kathy Baisley, and James Carpenter. 2014. <span>“Relaxing the Independent Censoring Assumption in the Cox Proportional Hazards Model Using Multiple Imputation.”</span> <em>Statistics in Medicine</em> 33 (27): 4681–94. https://doi.org/<a href="https://doi.org/10.1002/sim.6274">https://doi.org/10.1002/sim.6274</a>.
</div>
<div id="ref-mayo_23" class="csl-entry" role="listitem">
Mayo, Susan, and Yongman Kim. 2023. <span>“What Can Be Achieved with the Estimand Framework?”</span> <em>Statistics in Biopharmaceutical Research</em> 0 (ja): 1–8. <a href="https://doi.org/10.1080/19466315.2023.2173645">https://doi.org/10.1080/19466315.2023.2173645</a>.
</div>
<div id="ref-rubin_17" class="csl-entry" role="listitem">
Rubin, E. H., M. J. Scroggins, K. B. Goldberg, and Julia A Beaver. 2017. <span>“Strategies to Maximize Patient Participation in Clinical Trials.”</span> <em>American Society of Clinical Oncology Educational Book</em>, no. 37: 216–21. <a href="https://doi.org/10.1200/EDBK\_179803">https://doi.org/10.1200/EDBK\_179803</a>.
</div>
<div id="ref-unkel_19" class="csl-entry" role="listitem">
Unkel, Steffen, Marjan Amiri, Norbert Benda, Jan Beyersmann, Dietrich Knoerzer, Katrin Kupas, Frank Langer, et al. 2019. <span>“On Estimands and the Analysis of Adverse Events in the Presence of Varying Follow-up Times Within the Benefit Assessment of Therapies.”</span> <em>Pharmaceutical Statistics</em> 18 (March): 166–83.
</div>
<div id="ref-fda_endpoints" class="csl-entry" role="listitem">
U.S. Food and Drug Administration. 2007. <em><span class="nocase">Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics</span></em>. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics</a>.
</div>
</div></section></div></main> <!-- /main -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const isCodeAnnotation = (el) => {
    for (const clz of el.classList) {
      if (clz.startsWith('code-annotation-')) {                     
        return true;
      }
    }
    return false;
  }
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    text: function(trigger) {
      const codeEl = trigger.previousElementSibling.cloneNode(true);
      for (const childEl of codeEl.children) {
        if (isCodeAnnotation(childEl)) {
          childEl.remove();
        }
      }
      return codeEl.innerText;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
      let selectedAnnoteEl;
      const selectorForAnnotation = ( cell, annotation) => {
        let cellAttr = 'data-code-cell="' + cell + '"';
        let lineAttr = 'data-code-annotation="' +  annotation + '"';
        const selector = 'span[' + cellAttr + '][' + lineAttr + ']';
        return selector;
      }
      const selectCodeLines = (annoteEl) => {
        const doc = window.document;
        const targetCell = annoteEl.getAttribute("data-target-cell");
        const targetAnnotation = annoteEl.getAttribute("data-target-annotation");
        const annoteSpan = window.document.querySelector(selectorForAnnotation(targetCell, targetAnnotation));
        const lines = annoteSpan.getAttribute("data-code-lines").split(",");
        const lineIds = lines.map((line) => {
          return targetCell + "-" + line;
        })
        let top = null;
        let height = null;
        let parent = null;
        if (lineIds.length > 0) {
            //compute the position of the single el (top and bottom and make a div)
            const el = window.document.getElementById(lineIds[0]);
            top = el.offsetTop;
            height = el.offsetHeight;
            parent = el.parentElement.parentElement;
          if (lineIds.length > 1) {
            const lastEl = window.document.getElementById(lineIds[lineIds.length - 1]);
            const bottom = lastEl.offsetTop + lastEl.offsetHeight;
            height = bottom - top;
          }
          if (top !== null && height !== null && parent !== null) {
            // cook up a div (if necessary) and position it 
            let div = window.document.getElementById("code-annotation-line-highlight");
            if (div === null) {
              div = window.document.createElement("div");
              div.setAttribute("id", "code-annotation-line-highlight");
              div.style.position = 'absolute';
              parent.appendChild(div);
            }
            div.style.top = top - 2 + "px";
            div.style.height = height + 4 + "px";
            let gutterDiv = window.document.getElementById("code-annotation-line-highlight-gutter");
            if (gutterDiv === null) {
              gutterDiv = window.document.createElement("div");
              gutterDiv.setAttribute("id", "code-annotation-line-highlight-gutter");
              gutterDiv.style.position = 'absolute';
              const codeCell = window.document.getElementById(targetCell);
              const gutter = codeCell.querySelector('.code-annotation-gutter');
              gutter.appendChild(gutterDiv);
            }
            gutterDiv.style.top = top - 2 + "px";
            gutterDiv.style.height = height + 4 + "px";
          }
          selectedAnnoteEl = annoteEl;
        }
      };
      const unselectCodeLines = () => {
        const elementsIds = ["code-annotation-line-highlight", "code-annotation-line-highlight-gutter"];
        elementsIds.forEach((elId) => {
          const div = window.document.getElementById(elId);
          if (div) {
            div.remove();
          }
        });
        selectedAnnoteEl = undefined;
      };
      // Attach click handler to the DT
      const annoteDls = window.document.querySelectorAll('dt[data-target-cell]');
      for (const annoteDlNode of annoteDls) {
        annoteDlNode.addEventListener('click', (event) => {
          const clickedEl = event.target;
          if (clickedEl !== selectedAnnoteEl) {
            unselectCodeLines();
            const activeEl = window.document.querySelector('dt[data-target-cell].code-annotation-active');
            if (activeEl) {
              activeEl.classList.remove('code-annotation-active');
            }
            selectCodeLines(clickedEl);
            clickedEl.classList.add('code-annotation-active');
          } else {
            // Unselect the line
            unselectCodeLines();
            clickedEl.classList.remove('code-annotation-active');
          }
        });
      }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->



</body></html>